Crystal Bioscience Acquired By Ligand For Up To $30.5M
Emeryville-based Crystal Bioscience, the developer of chicken-derived, human antibody production technology, has been acquired by Ligand Pharmaceuticals. Ligand said it agreed to pay $25M in cash plus additional potential payments of up to $10.5M based on success-based milestones and revenue sharing for Crystal Bioscience.
posted on Wednesday, October 4, 2017
Related companies:
Crystal Clear Technologies, Inc.
Related stories:
> Open Monoclocal Technology Acquired By Ligand For $178M
> Twist Bioscience Buys Genome Compiler
> Solaicx Acquired By MEMC
> Twist Bioscience Gets $37M
> SARcode Bioscience Acquired By Shire
silicontap.com Home